Esperion Therapeutics Analyst Ratings

In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease.
Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. (tipranks.com)

Analyst ratings:
11/10/2020 Credit Suisse Group $45.00
10/15/2020 Bank of America $52.00
9/29/2020 JPMorgan Chase & Co. $35.00
8/11/2020 Needham & Company LLC $158.00
8/10/2020 Stifel Nicolaus $75.00

Today`s price: usd27.71

Please leave me a message if you want to test the buy and sell indicators that i am using.